By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile



100 Cumming Center, Suite 151-B
Suite A225
Beverly  Massachusetts  01915  U.S.A.
Phone: 978-236-8717 Fax: 978-921-6564


Company News
Cellceutix (CTIX) Provides Initial Observations Of Completed ABSSSI Phase 2b Trial; Company Submits Investigational New Drug Application To FDA For Phase 2 Trial Of Brilacidin-OM For Oral Mucositis 9/10/2014 11:31:01 AM
Cellceutix (CTIX) To Present At Rodman & Renshaw's 16th Annual Global Investment Conference 9/8/2014 12:37:20 PM
Cellceutix (CTIX) Appoints Dr. Barry Schechter To Board Of Directors As Company Focuses On Meeting Requirements For Stock Exchange Uplisting 9/2/2014 2:05:32 PM
Cellceutix (CTIX) Completes Enrollment In Phase 2b Clinical Trial Of Brilacidin For Acute Bacterial Skin And Skin Structure Infections (ABSSSI) 8/19/2014 11:31:24 AM
Cellceutix (CTIX) Anti-Psoriasis Drug Prurisol Meets Primary Endpoint Of Clinical Trial 8/7/2014 10:16:59 AM
Cellceutix (CTIX) Believes Brilacidin On Track To Help U.S. Avoid Falling Into Post-Antibiotic Era; Completion of Enrollment In Phase 2b Trial For Acute Bacterial Skin And Skin Structure Infections Expected This Month 8/4/2014 11:31:29 AM
Cellceutix (CTIX) Announces Breakthrough In The Formulation Of Its Novel Antibiotic Brilacidin™, Plans Studies To Treat Diabetic Foot Ulcers 7/15/2014 11:29:41 AM
Cellceutix (CTIX) Brilacidin ABSSSI Trial Gets Positive Review By Data Safety Monitoring Board; Best Possible Outcome, No Treatment-Related Serious Adverse Events (SAEs) 7/7/2014 12:31:02 PM
Cellceutix (CTIX) Anti-Fungal Compounds Awarded $1.5 Million SBIR Grant 6/23/2014 8:51:11 AM
Cellceutix (CTIX) Clinical Trial Of Anti-Cancer Drug Kevetrin Entering Eighth Cohort 6/16/2014 11:19:51 AM